The 9th IAS Conference on HIV Science (IAS 2017), organised by the International AIDS Society, took place in Paris, France, from 23-26 July 2017.

Conference highlights

HIV Community Forum

Watch the highlights film from the HIV Community Forum, hosted by NAM aidsmap.

Conference bulletins

Catch up on conference news with our summary bulletins. Available in English, French, Italian, Russian, Portuguese and Spanish.

Cure research

Why curing HIV may be like curing cancer – and may be as difficult.


$90-$90-$90 target

Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows.

Treatment as prevention

International study of gay couples reports no transmissions from an HIV-positive partner on treatment.

PrEP

France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic.


HIV testing

Can self-testing engage 'hard-to-reach' men with HIV testing?

Treatment as prevention

Swaziland: new infections halved in five years as HIV treatment scales up.

90-90-90 target

World on track to reach the 90-90-90 targets for HIV treatment by 2020.


aidsmap news from IAS 2017

← First123Next →

Editors' picks from other sources

Email bulletins

Sign up for our news bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Tweets from IAS 2017

  • Zero HIV transmission in gay sex when virally suppressed, 40k condomless sex acts. End of debate? Think so. #IAS2017 https://t.co/7aR6JjdVVq27 Jul 2017 02:47
  • A long-acting #PrEP, injected every 8 weeks, shows promise. If effective, it could be a game changer. #IAS2017: https://t.co/k3Gs6ISAEW27 Jul 2017 12:38
  • #IAS2017 was great! We have come far in the fight against #HIV (e.g., #PrEP) but we have a long way to go (e.g., #EndStigma) + more funding27 Jul 2017 09:38
  • #IAS2017 finished yestareday with over 7800 participants. Basic research sessions offered excellent science and had impressive attendance.27 Jul 2017 09:32
  • Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows https://t.co/vSq1fWhqwP #IAS201727 Jul 2017 09:14
  • South Africa will be producing generic #dolutegravir for the region #IAS2017 @AfrocabH27 Jul 2017 09:13
  • "Meaningful involvement of #keypopulations and #PLHIV in shaping research priorities must remain an unwavering principle." #IAS2017 #HIV26 Jul 2017 07:30
  • M. Lichterfeld at #IAS2017, in basic science rapporteur session, reaffirms that early #HIV testing can better prevent infection spread.26 Jul 2017 04:46
  • O.Mellouk @ITPCglobal: Gilead pricing wrecked countries' budgets & forced people to run from country to country to get sofosbuvir #IAS201726 Jul 2017 04:32
  • Demonstration projects explore the feasibility of PrEP for adolescents and young women in South Africa https://t.co/cIy5MaPhT8 #IAS201726 Jul 2017 04:18
  • The first slides from #IAS2017 have been uploaded to https://t.co/MZA7a9bCpr many many more to come. Free access, register now...26 Jul 2017 04:07
  • "Better feedback between #keypops & providers leads to accountability & continuous quality improvement." - Cameron Wolf @USAIDGH #IAS201726 Jul 2017 02:20
  • @WHO endorses that buyer's clubs can be seriously considered for getting access to drugs when all other options are unaffordable #IAS201726 Jul 2017 02:05
  • #IAS2017 #ambassadorBirx on #HSS & #hiv response: we didn't just strengthen existing health systems, we needed to create what did not exist26 Jul 2017 02:03
  • In #Kenya we’re creating demand for #HIV services among young women through peer edu & innovative methods like television programs. #IAS201726 Jul 2017 02:00
  • "Investments in research &prevention tools are key but we need to understand why existing ones aren't being used" @MarijkeWijnroks #IAS201726 Jul 2017 01:41
  • To make drugs affordable for all, we work with the MPP and its voluntary licensing model - Jessica Burry from @MSF_access #IAS2017 #EndAIDS26 Jul 2017 01:11
  • "We must make [#HIV] facility-based services more acceptable, accessible, affordable, & equitable." - Kate Thomson @GlobalFund #IAS2017 #KPs26 Jul 2017 01:01
  • Among Kenyan/Ugandan women at high HIV risk, contraceptive use didn't appear to impact PrEP adherence #IAS2017 https://t.co/FW9iDVSwE726 Jul 2017 12:51
  • "Le travail des gouvernements est de négocier les prix des médicaments, pas juste d'enregistrer ces prix". #IAS201726 Jul 2017 12:43
  • New #HIV vaccine meets the criteria to start large scale phase III human trials this year. #IAS2017 https://t.co/HV2wzWk3v826 Jul 2017 12:30
  • Confidence d'un chercheur du Malawi (HIV/Tuberculose) "c'est dur de voir les gens mourir de maladies qu'on peut prévenir." #IAS201726 Jul 2017 12:05
  • There has been a tremendous increase in uptake of #hivselftest but more pronounced increase in women - Karin Hatzold @PSIimpact #ias201726 Jul 2017 11:50
  • Unacceptable that 18% of 27000 HIV-related TB cases died in Europe in 2015. Living with #HIV. Dying from #TB @HIVTB @HarmReduction #IAS201726 Jul 2017 11:21
  • Hanne Zimmermann's presentation on motivations for event-driven vs. daily #PrEP use in #Dutch men is excellent. And she's cool #ias201726 Jul 2017 10:26
  • #TB screening of pregnant women living with HIV increased TB detection 10x & reduced infant mortality in #SouthAfrica #IAS201726 Jul 2017 10:22
  • Lots of #IAS2017 sessions have been filmed and are being published on the @IAS_conference YouTube channel: https://t.co/OgzOR1MTFv26 Jul 2017 08:22
  • Fantastic session on #women & #HIV-from #PMTCT to #menopause.Much work to be done to increase inclusion of women in HIV research #IAS201726 Jul 2017 10:12
  • Coceka Mnyani: #HIV remains leading cause of death for women aged 30-49 globally #IAS201726 Jul 2017 09:25
  • Interesting to hear more about 4-5 days a week ART, from Anna Turkova of @MRCCTU and GOSH... #IAS201726 Jul 2017 09:18
  • Ayesha of CAPRISA: voluntary male circumcision not only protects men, it also reduces chances of women contracting #HIV and #Herpes #ias201726 Jul 2017 09:17
  • Ipergay trial: PrEP still protected people who had less sex and used it less often https://t.co/DDV5Vz7CFp #IAS201726 Jul 2017 08:57
  • PADDLE "small numbers but strong message". No. Small numbers = weak message. Too often we learn pilots are not always replicated #IAS201726 Jul 2017 09:12
  • International study of gay couples reports no transmissions from an #HIV-positive partner on treatment https://t.co/YevmhHhsZ3 #IAS201725 Jul 2017 02:28
  • "When #keypopulations are ignored or stigmatized, #HIV spreads." - @LindaGailBekker #IAS2017 @iasociety @DTHF_SA25 Jul 2017 02:01
  • Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection https://t.co/uwJ1gE9Zxz #IAS201726 Jul 2017 08:57
  • Young people are not a homogenous group and we can't expect to reach them with a one-size-fits-all approach -@ygpillay #IAS2017 #youth26 Jul 2017 08:46
  • Fabien Zoulim: #HBV viral replication can continue in liver despite 'viral suppression,' explains need for lifelong #hepB therapy #IAS201726 Jul 2017 08:19
  • Alexandra Calmy: As middle-income countries shift away from efavirenz, expanding access to generic drugs for #HIV is indispensable #IAS201726 Jul 2017 07:50
  • Women represent less than 20% of #HIV drug trial participants. #IAS201726 Jul 2017 07:45
  • Can self testing engage 'hard to reach' men with HIV testing? #IAS2017 https://t.co/xklhqs3Xgd26 Jul 2017 07:06
  • 12000 insertive sex msm, 0 transmissions in couples, 3 from outside, tasp and varying degrees of prep #IAS201725 Jul 2017 01:43
  • Dr. Gotham: $90 per person can be new ceiling price for treating #HIV, #TB, #HCV & #HBV. #IAS2017 @HIVpxresearch @IAS_conference25 Jul 2017 01:42
  • #IAS2017: AIDS-related deaths comprise 54% of overall inpatient deaths in Nsanje hospital, #Malawi. Of these 29% occur within first 48 hours25 Jul 2017 01:15
  • New @WHO guidance says start #HIV treatment within 7 days of diagnosis - & at once if patient is willing. #IAS2017 https://t.co/2XYY4mvLun25 Jul 2017 01:13
  • #IAS2017 #MSF calls for the wide implementation of new WHO guidelines for advanced HIV and strengthened hospital-based care.25 Jul 2017 12:42
  • French #PrEP Ipergay trial found 29% of participants report at least one occasion of #Chemsex, also associated with high risk sex. #IAS201725 Jul 2017 01:03
  • #IAS2017 #MSF: While increased access to ART has led to reduced deaths, these gains have been limited for those people with advanced HIV.25 Jul 2017 12:39
  • "La situation du #Sida en Europe de l'est est catastrophique, on peut le dire" Michel #Kazatchkine #ONU #IAS201725 Jul 2017 12:36
  • New integrase inhibitor bictegravir works well for first-line HIV treatment https://t.co/AutuZRfCRu25 Jul 2017 07:51

Official conference website

Find out more about the conference and view the programme on the official conference website.

Visit the conference website >

aidsmap news apps

Keep up to date with the latest HIV news using the free aidsmap news apps for android and iPhone.

Download the app >

NAM's news coverage of the International AIDS Society's Conference on HIV Science has been made possible thanks to support from Gilead Sciences Europe Ltd. and Merck & Co. NAM's wider conference news reporting services have been supported by Janssen and ViiV Healthcare.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.